sofosbuvir   Click here for help

GtoPdb Ligand ID: 7368

Synonyms: GI-7977 | PSI 7977 | Sovaldi®
Approved drug PDB Ligand
sofosbuvir is an approved drug (FDA (2013), EMA (2014))
Compound class: Synthetic organic
Comment: Sofosbuvir is a nucleotide analogue whose action inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It acts as a chain terminator to limit viral RNA replication.
Sofosbuvir is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 167.99
Molecular weight 529.16
XLogP 1.93
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(OC(=O)C(NP(=O)(Oc1ccccc1)OCC1OC(C(C1O)(C)F)n1ccc(=O)[nH]c1=O)C)C
Isomeric SMILES CC(OC(=O)[C@@H](N[P@@](=O)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)F)n1ccc(=O)[nH]c1=O)C)C
InChI InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
InChI Key TTZHDVOVKQGIBA-IQWMDFIBSA-N
No information available.
Summary of Clinical Use Click here for help
Used in combination therapy to treat hepatitis C viral infection with or without co-infection with HIV.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Prevents HCV viral replication by inhibiting HCV NS5B polymerase.
External links Click here for help